340 related articles for article (PubMed ID: 22126936)
1. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
Akerblom Å; Wallentin L; Siegbahn A; Becker RC; Budaj A; Buck K; Giannitsis E; Horrow J; Husted S; Katus HA; Steg PG; Storey RF; Åsenblad N; James SK
Clin Chem; 2012 Jan; 58(1):190-9. PubMed ID: 22126936
[TBL] [Abstract][Full Text] [Related]
2. Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.
Akerblom A; Wallentin L; Siegbahn A; Becker RC; Budaj A; Horrow J; Husted S; Katus H; Claeys MJ; Storey RF; Asenblad N; James SK
Am Heart J; 2012 Nov; 164(5):728-34. PubMed ID: 23137503
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
Wallentin L; Lindholm D; Siegbahn A; Wernroth L; Becker RC; Cannon CP; Cornel JH; Himmelmann A; Giannitsis E; Harrington RA; Held C; Husted S; Katus HA; Mahaffey KW; Steg PG; Storey RF; James SK;
Circulation; 2014 Jan; 129(3):293-303. PubMed ID: 24170388
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Risk Prediction With the CKD-EPI and MDRD Equations in Non-ST-Segment Elevation Acute Coronary Syndrome.
Flores-Blanco PJ; López-Cuenca Á; Januzzi JL; Marín F; Sánchez-Martínez M; Quintana-Giner M; Romero-Aniorte AI; Valdés M; Manzano-Fernández S
Clin Cardiol; 2016 Sep; 39(9):507-15. PubMed ID: 27249221
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome.
Eggers KM; Lagerqvist B; Venge P; Wallentin L; Lindahl B
J Am Coll Cardiol; 2009 Jul; 54(4):357-64. PubMed ID: 19608034
[TBL] [Abstract][Full Text] [Related]
6. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
7. Time course changes of cystatin C and inflammatory and biochemical markers in non-ST-elevation acute coronary syndromes.
De Servi S; Mariani G; Piatti L; Leoncini M; Rubartelli P; Pitì A; Curello S; Galdangelo F; Vandoni P; Rossetti E; Mariani M; Boschetti E; Re G; Loznicker M
J Cardiovasc Med (Hagerstown); 2014 Jan; 15(1):42-7. PubMed ID: 24492354
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
Lindholm D; Varenhorst C; Cannon CP; Harrington RA; Himmelmann A; Maya J; Husted S; Steg PG; Cornel JH; Storey RF; Stevens SR; Wallentin L; James SK
Eur Heart J; 2014 Aug; 35(31):2083-93. PubMed ID: 24727884
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.
Wang H; Qi J; Li Y; Tang Y; Li C; Li J; Han Y
Br J Clin Pharmacol; 2018 Jan; 84(1):88-96. PubMed ID: 28921624
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes.
Goldstein SA; Newby LK; Cyr DD; Neely M; Lüscher TF; Brown EB; White HD; Ohman EM; Roe MT; Hamm CW
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28400368
[TBL] [Abstract][Full Text] [Related]
11. Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome.
Ristiniemi N; Lund J; Tertti R; Christensson A; Ilva T; Porela P; Pulkki K; Pettersson K
Clin Biochem; 2012 May; 45(7-8):535-40. PubMed ID: 22394460
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
[TBL] [Abstract][Full Text] [Related]
13. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Andell P; James SK; Cannon CP; Cyr DD; Himmelmann A; Husted S; Keltai M; Koul S; Santoso A; Steg PG; Storey RF; Wallentin L; Erlinge D;
J Am Heart Assoc; 2015 Oct; 4(10):e002490. PubMed ID: 26452988
[TBL] [Abstract][Full Text] [Related]
14. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.
Bansal N; Katz R; Dalrymple L; de Boer I; DeFilippi C; Kestenbaum B; Park M; Sarnak M; Seliger S; Shlipak M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):205-14. PubMed ID: 25605700
[TBL] [Abstract][Full Text] [Related]
15. Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial.
Pollack CV; Davoudi F; Diercks DB; Becker RC; James SK; Lim ST; Schulte PJ; Spinar J; Steg PG; Storey RF; Himmelmann A; Wallentin L; Cannon CP;
Clin Cardiol; 2017 Jun; 40(6):390-398. PubMed ID: 28598510
[TBL] [Abstract][Full Text] [Related]
16. Major bleeding risk prediction using Chronic Kidney Disease Epidemiology Collaboration and Modification of Diet in Renal Disease equations in acute coronary syndrome.
Flores-Blanco PJ; López-Cuenca Á; Januzzi JL; Marín F; Sánchez-Martínez M; Quintana-Giner M; Romero-Aniorte AI; Valdés M; Manzano-Fernández S
Eur J Clin Invest; 2015 Apr; 45(4):385-93. PubMed ID: 25661774
[TBL] [Abstract][Full Text] [Related]
17. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome.
Taglieri N; Fernandez-Berges DJ; Koenig W; Consuegra-Sanchez L; Fernandez JM; Robles NR; Sánchez PL; Beiras AC; Orbe PM; Kaski JC;
Atherosclerosis; 2010 Mar; 209(1):300-5. PubMed ID: 19819453
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Husted S; James S; Becker RC; Horrow J; Katus H; Storey RF; Cannon CP; Heras M; Lopes RD; Morais J; Mahaffey KW; Bach RG; Wojdyla D; Wallentin L;
Circ Cardiovasc Qual Outcomes; 2012 Sep; 5(5):680-8. PubMed ID: 22991347
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of serum biomarkers in association with TIMI risk score for acute coronary syndromes.
Manenti ER; Bodanese LC; Camey SA; Polanczyk CA
Clin Cardiol; 2006 Sep; 29(9):405-10. PubMed ID: 17007172
[TBL] [Abstract][Full Text] [Related]
20. Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet Inhibition and Patient Outcomes (PLATO) study.
Åkerblom A; Wallentin L; Larsson A; Siegbahn A; Becker RC; Budaj A; Himmelmann A; Horrow J; Husted S; Storey RF; Asenblad N; James SK;
Clin Chem; 2013 Sep; 59(9):1369-75. PubMed ID: 23698074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
